Defining Characteristics of Types I and II Apoptotic Cells in Response to TRAIL

by Nesrin Özören, Wafik S. El-Deiry
Published 2002-01-01

Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology

by Wafik S. El-Deiry, Giuseppe Giaccone
Published 2021-03-01

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies

by Nicholas R. Liguori, Nicholas R. Liguori, Young Lee, William Borges, Lanlan Zhou, Lanlan Zhou, Lanlan Zhou, Lanlan Zhou, Christopher Azzoli, Christopher Azzoli, Christopher Azzoli, Wafik S. El-Deiry, Wafik S. El-Deiry, Wafik S. El-Deiry, Wafik S. El-Deiry, Wafik S. El-Deiry
Published 2021-08-01

Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action

by Wafik S. El-Deiry, Christina Leah B. Kline
Published 2013-08-01

Targeting the Integrated Stress Response in Cancer Therapy

by Xiaobing Tian, Xiaobing Tian, Xiaobing Tian, Xiaobing Tian, Shengliang Zhang, Shengliang Zhang, Shengliang Zhang, Shengliang Zhang, Lanlan Zhou, Lanlan Zhou, Lanlan Zhou, Lanlan Zhou, Attila A. Seyhan, Attila A. Seyhan, Attila A. Seyhan, Attila A. Seyhan, Liz Hernandez Borrero, Yiqun Zhang, Wafik S. El-Deiry, Wafik S. El-Deiry, Wafik S. El-Deiry, Wafik S. El-Deiry, Wafik S. El-Deiry
Published 2021-09-01

Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.

by Joshua E Allen, Roslyn N Crowder, Wafik S El-Deiry
Published 2016-01-01

First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.

by Joshua E Allen, Roslyn N Crowder, Wafik S El-Deiry
Published 2015-01-01

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

by Andre De Souza, Fabio A. Tavora, Devalingam Mahalingam, Pamela N. Munster, Howard P. Safran, Wafik S. El-Deiry, Wafik S. El-Deiry, Benedito A. Carneiro
Published 2020-10-01

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)

by Wafik S. El-Deiry, Wafik S. El-Deiry, Arthur Winer, Michael Slifker, Stanford Taylor, Blythe J. S. Adamson, Neal J. Meropol, Eric A. Ross, Eric A. Ross
Published 2019-03-01

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanism...

by Jessica Wagner, C. Leah Kline, Lanlan Zhou, Vladimir Khazak, Wafik S. El-Deiry
Published 2018-01-01

Circulating tumor cells: silent predictors of metastasis [version 1; referees: 2 approved]

by LanLan Zhou, David T. Dicker, Elizabeth Matthew, Wafik S. El-Deiry, R. Katherine Alpaugh
Published 2017-08-01

Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling

by Elizabeth M. Matthew, Zhaohai Yang, Suraj Peri, Mark Andrake, Roland Dunbrack, Eric Ross, Wafik S. El-Deiry
Published 2018-03-01

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

by Xiaobing Tian, Nagib Ahsan, Amriti Lulla, Avital Lev, Philip Abbosh, David T. Dicker, Shengliang Zhang, Wafik S. El-Deiry
Published 2021-03-01

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor...

by Yiqun Zhang, Lanlan Zhou, Howard Safran, Robyn Borsuk, Rishi Lulla, Nikos Tapinos, Attila A. Seyhan, Wafik S. El-Deiry
Published 2021-08-01

Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2

by Kelsey E Huntington, Anna D Louie, Chun Geun Lee, Jack A Elias, Eric A Ross, Wafik S El-Deiry
Published 2021-01-01

Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer

by Joshua E. Allen, Jean-Nicolas Gallant, David T. Dicker, Shantu Amin, Rosalyn B. Irby, Arun K. Sharma, Wafik S. El-Deiry
Published 2013-01-01

The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.

by Joshua E Allen, Jean-Nicolas Gallant, David T Dicker, Shantu Amin, Rosalyn B Irby, Arun K Sharma, Wafik S El-Deiry
Published 2013-01-01

Correction: The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer.

by Joshua E. Allen, Jean-Nicolas Gallant, David T. Dicker, Shantu Amin, Rosalyn B. Irby, Arun K. Sharma, Wafik S. El-Deiry
Published 2013-01-01

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

by Liz Hernandez Borrero, David T Dicker, John Santiago, Jennifer Sanders, Xiaobing Tian, Nagib Ahsan, Avital Lev, Lanlan Zhou, Wafik S El-Deiry
Published 2021-07-01

Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.

by Junaid Abdulghani, Joshua E Allen, David T Dicker, Yingqiu Yvette Liu, David Goldenberg, Charles D Smith, Robin Humphreys, Wafik S El-Deiry
Published 2013-01-01